GLUE - Monte Rosa Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.75
DETAILS
HIGH:
$37.00
LOW:
$22.00
MEDIAN:
$34.00
CONSENSUS:
$31.75
UPSIDE:
68.79%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Revenue | 123.7 | 75.6 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 8.4 | 8.1 | 6.2 | 0 | 0 | 0.5 | 0.1 |
| Gross Profit | 115.3 | 67.5 | (6.2) | 0 | 0 | (0.5) | (0.1) |
| Operating Expenses | |||||||
| R&D Expenses | 141.5 | 121.6 | 105.0 | 85.1 | 57.2 | 23.5 | 7.3 |
| SG&A Expenses | 36.4 | 35.2 | 32.0 | 27.3 | 15.7 | 4.0 | 0.6 |
| Other Expenses | (8.4) | (8.1) | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 169.5 | 148.6 | 137.1 | 112.4 | 72.9 | 27.5 | 8.0 |
| Operating Income | |||||||
| Operating Income | (54.2) | (81.1) | (143.3) | (112.4) | (72.9) | (28.0) | (8.0) |
| Interest Expense | 0 | 0 | 0 | 3.8 | 0 | 0 | 0.0 |
| Interest Income | 12.9 | 10.6 | 9.3 | 3.8 | 0.0 | 0.0 | 0.0 |
| Profitability | |||||||
| EBITDA | (45.9) | (73.0) | (137.1) | (108.6) | (70.8) | (27.5) | (7.7) |
| EBIT | (54.2) | (81.1) | (143.3) | (112.4) | (72.9) | (28.0) | (7.7) |
| Income Before Tax | (39.7) | (70.1) | (135.0) | (108.5) | (74.0) | (35.9) | (7.7) |
| Income Tax Expense | (1.1) | 2.6 | 0.3 | 0 | 0 | 0 | 0 |
| Net Income | (38.6) | (72.7) | (135.4) | (108.5) | (74.0) | (35.9) | (8.0) |
| Per Share Data | |||||||
| EPS (Basic) | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| EPS (Diluted) | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Shares Outstanding | 83.1 | 73.9 | 51.4 | 47.2 | 46.5 | 44.0 | 44.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Current Assets | |||||||
| Cash & Cash Equivalents | 129.9 | 224.3 | 128.1 | 54.9 | 346.1 | 41.7 | 6.0 |
| Short-Term Investments | 247.2 | 147.9 | 104.3 | 207.9 | 0 | 0 | 0 |
| Net Receivables | 4.6 | 0.2 | 0.5 | 7.7 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 11.5 | 5.1 | 3.3 | 5.4 | 0 | 0.1 | 3.2 |
| Total Current Assets | 393.2 | 377.4 | 236.2 | 275.9 | 348.7 | 43.6 | 9.8 |
| Non-Current Assets | |||||||
| Property, Plant & Equipment | 50.4 | 56.3 | 62.6 | 61.9 | 12.3 | 4.6 | 1.3 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 5.3 | 1.2 | 0 |
| Other Non-Current Assets | 5.1 | 5.0 | 4.9 | 4.6 | 0 | 0 | 0 |
| Total Non-Current Assets | 55.5 | 61.3 | 67.5 | 66.5 | 17.7 | 5.8 | 1.3 |
| Total Assets | 448.7 | 438.7 | 303.8 | 342.4 | 366.3 | 49.4 | 11.1 |
| Current Liabilities | |||||||
| Account Payables | 3.5 | 17.2 | 11.2 | 7.9 | 6.6 | 7.1 | 3.2 |
| Short-Term Debt | 4.4 | 0 | 0 | 0 | 0 | 0 | 0.8 |
| Deferred Revenue | 29.6 | 117.2 | 17.7 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 26.7 | 11.6 | 9.3 | 10.6 | 0.8 | 21.1 | 0 |
| Total Current Liabilities | 64.2 | 156.9 | 46.6 | 25.6 | 16.6 | 29.3 | 4.3 |
| Non-Current Liabilities | |||||||
| Long-Term Debt | 34.8 | 0 | 0 | 0 | 0 | 67.8 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.3 | 3.7 | 2.7 | 1.5 | 2.2 | 0 | 18.9 |
| Total Non-Current Liabilities | 151.4 | 58.9 | 77.9 | 45.4 | 2.2 | 68.8 | 18.9 |
| Total Liabilities | 215.6 | 215.8 | 124.5 | 71.0 | 18.8 | 98.1 | 23.2 |
| Stockholders' Equity | |||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Retained Earnings | (477.2) | (438.6) | (365.9) | (230.5) | (122.0) | (48.1) | (12.2) |
| Accumulated Other Comprehensive Income | (3.8) | (3.4) | (2.7) | (1.8) | (2.0) | (1.1) | 0 |
| Total Stockholders' Equity | 233.1 | 222.9 | 179.2 | 271.4 | 347.5 | (48.7) | (12.1) |
| Total Liabilities & Equity | 448.7 | 438.7 | 303.8 | 342.4 | 366.3 | 49.4 | 11.1 |
| Debt Metrics | |||||||
| Total Debt | 39.2 | 42.7 | 46.0 | 47.0 | 0 | 67.8 | 0.8 |
| Net Debt | (90.7) | (181.5) | (82.1) | (7.9) | (346.1) | 26.1 | (5.2) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | (38.6) | (72.7) | (135.4) | (108.5) | (74.0) | (35.9) | (7.7) |
| Depreciation & Amortization | 8.4 | 8.1 | 6.2 | 3.7 | 2.1 | 0.5 | 0.1 |
| Stock-Based Compensation | 18.9 | 18.1 | 16.7 | 11.7 | 5.2 | 0.4 | 0 |
| Change in Working Capital | (9.2) | 91.4 | 72.5 | (2.1) | 6.3 | 4.3 | 1.8 |
| Other Non-Cash Items | (2.2) | (2.9) | (3.8) | 2.8 | 1.0 | 7.7 | (0.3) |
| Operating Cash Flow | (22.8) | 42.0 | (43.8) | (92.5) | (59.4) | (23.1) | (6.2) |
| Investing Activities | |||||||
| Capital Expenditure | (4.7) | (4.0) | (19.0) | (12.9) | (9.7) | (3.4) | (1.4) |
| Acquisitions | 0 | 0 | 0.1 | 0.1 | 0.1 | 0 | 0 |
| Purchases of Investments | (376.7) | (230.4) | (103.2) | (384.4) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 279.5 | 189.9 | 210.9 | 178 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (101.8) | (44.5) | 88.8 | (219.2) | (9.7) | (3.4) | (1.4) |
| Financing Activities | |||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 |
| Stock Repurchased | 0 | (0.6) | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 98.6 | 0 | 0.4 | (3.2) | 0 | 0 |
| Financing Cash Flow | 30.4 | 98.9 | 27.5 | 20.5 | 377.6 | 60.1 | 15 |
| Cash Position | |||||||
| Net Change in Cash | (94.3) | 96.4 | 72.5 | (291.2) | 308.5 | 32.5 | 7.4 |
| Cash at Beginning | 229.1 | 132.7 | 60.2 | 351.4 | 42.9 | 9.2 | 1.8 |
| Cash at End | 134.8 | 229.1 | 132.7 | 60.2 | 351.4 | 41.7 | 9.2 |
| Free Cash Flow | (27.5) | 38.0 | (62.8) | (105.4) | (69.1) | (26.4) | (7.6) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 123.7 | 75.6 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 115.3 | 67.5 | (6.2) | 0 | 0 | (0.5) | (0.1) |
| Operating Income | (54.2) | (81.1) | (143.3) | (112.4) | (72.9) | (28.0) | (8.0) |
| Net Income | (38.6) | (72.7) | (135.4) | (108.5) | (74.0) | (35.9) | (8.0) |
| EPS (Diluted) | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Balance Sheet | |||||||
| Cash & Equivalents | 129.9 | 224.3 | 128.1 | 54.9 | 346.1 | 41.7 | 6.0 |
| Total Assets | 448.7 | 438.7 | 303.8 | 342.4 | 366.3 | 49.4 | 11.1 |
| Total Debt | 39.2 | 42.7 | 46.0 | 47.0 | 0 | 67.8 | 0.8 |
| Stockholders' Equity | 233.1 | 222.9 | 179.2 | 271.4 | 347.5 | (48.7) | (12.1) |
| Cash Flow | |||||||
| Operating Cash Flow | (22.8) | 42.0 | (43.8) | (92.5) | (59.4) | (23.1) | (6.2) |
| Capital Expenditure | (4.7) | (4.0) | (19.0) | (12.9) | (9.7) | (3.4) | (1.4) |
| Free Cash Flow | (27.5) | 38.0 | (62.8) | (105.4) | (69.1) | (26.4) | (7.6) |